Results 61 to 70 of about 6,658 (202)

Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database

Cancer Medicine, Volume 15, Issue 10, October 2026.
This real‐world study of the Flatiron Health database found that first‐line treatment with abiraterone versus enzalutamide was associated with significantly shorter overall survival, treatment duration, and time to subsequent treatment in patients with chemotherapy‐ and androgen receptor pathway inhibitor‐naïve metastatic castration‐resistant prostate ...
Daniel J. George, Jasmina I. Ivanova, Maëlys Touya, Betty Thompson, Jonathan Assayag, Benjamin Li, Nikolaos Kountouris, Gordon Siu, Stephen J. Freedland   +8 more
wiley   +1 more source

The evolving role of immunotherapy in ovarian cancer

Cancer, Volume 132, Issue 18, 15 September 2026.
Abstract Ovarian cancer remains a major cause of gynecologic cancer mortality; and, although immune checkpoint inhibitors have transformed treatment in other solid tumors, their activity in ovarian cancer has been limited by tumor heterogeneity, an immunosuppressive tumor microenvironment, and the lack of robust predictive biomarkers.
Ana Carolina Veneziani, Laura Venegas, Amit M. Oza   +2 more
wiley   +1 more source

Rucaparib-mediated vasodilation of rat vascular tissue may be partially dependent on myosin light chain kinase.

, 2015
Panel A; rucaparib (closed squares), nicotinamide (open squares) and ML-9 (open triangles) inhibit smooth muscle contraction in PE-constricted rat tail artery. Artery sections were constricted using 10 μM PE before perfusion with a solution containing 10
Tracy Robson (282407), Hiu-Fung Yuen (276126), Declan O’Rourke (692863), Martin G. O’Rourke (692861), Cian M. McCrudden (276127), Chris Hagan (692868), Joe M. O’Sullivan (275899), David G. Hirst (282406), Huw D. Thomas (114714), Nicola J. Curtin (351064), Kim E. Cherry (692862), Patrick Keane (692866), Chris Shaw (285026), Kaye J. Williams (692869), Muhammad Babur (692864), Brian A. Telfer (692865), Thiagarajan Nambirajan (692867)   +16 more
core   +1 more source

Preclinical evaluation of the PARP inhibitor rucaparib in combination with PD-1 and PD-L1 inhibition in a syngeneic BRCA1 mutant ovarian cancer model [PDF]

, 2017
Background: Rucaparib (CO-338) is an oral small molecule inhibitor of poly(ADP-ribose) polymerase (PARP)-1, PARP-2 and PARP-3 that has shown clinical activity in patients with BRCA1 and BRCA2 mutated advanced ovarian cancer. Monoclonal antibodies against
Harding, TC, Liliane Robillard, Andrew D. Simmons, Lin, K, Raponi, M, Simmons, AD, Robillard, L, Kristeleit, RS, Sandra Orsulic, Loehr, A, Mitch Raponi, Andrea Loehr, Orsulic, S, Rebecca S. Kristeleit, Nguyen, M, Minh Nguyen, Thomas C. Harding, Kevin Lin   +17 more
core   +1 more source

Cytostatic Bacterial Metabolites Interfere with 5-Fluorouracil, Doxorubicin and Paclitaxel Efficiency in 4T1 Breast Cancer Cells

Molecules
The microbiome is capable of modulating the bioavailability of chemotherapy drugs, mainly due to metabolizing these agents. Multiple cytostatic bacterial metabolites were recently identified that have cytostatic effects on cancer cells. In this study, we
Szandra Schwarcz, Petra Nyerges, Tímea Ingrid Bíró, Eszter Janka, Péter Bai, Edit Mikó   +5 more
doaj   +1 more source

Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report

BMC Cancer, 2020
Background Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for the treatment of breast cancer susceptibility genes 1 and 2 (BRCA1/2) mutant ovarian and breast cancers, and are now being evaluated in metastatic castration-resistant prostate ...
Andrew D. Simmons, Minh Nguyen, Elias Pintus   +2 more
doaj   +1 more source

Versatile Detection of Cellular Protein via Fluorescence Anisotropy

Advanced Science, Volume 13, Issue 51, 14 September 2026.
Cell Lysate Fluorescence Anisotropy (CFAST) utilizes long lifetime dye‐labeled nanobodies for rapid protein quantification in minimally purified, complex cell lysate. When coupled with cellular thermal shift, CFAST allows high‐throughput detection of endogenous protein‐small molecule engagement, facilitating the discovery of novel binders for ...
Qing Tang, Yuan‐Ping Wei, Ricky Ruiqi Ma, Na Wei, Tammy Zihan Zhou, Hilary Kung‐Yu Ho, Zafar Iqbal Bhat, Iqra Ishrat, Xiaoyu Li, Judy Wai Ping Yam, Yung Hou Wong, Qiankun Wang, Justin L. Tan   +12 more
wiley   +1 more source

P2 receptor blockade abrogates rucaparib-evoked vasodilation.

, 2015
Panel A; broad-spectrum antagonism of P2 receptors using suramin (inverted open triangles) abrogated rucaparib-evoked relaxation in rat tail artery (left) and aorta (right). Panel B; suramin itself was without vasoactivity, demonstrable by its failure to
Tracy Robson (282407), Hiu-Fung Yuen (276126), Declan O’Rourke (692863), Martin G. O’Rourke (692861), Cian M. McCrudden (276127), Chris Hagan (692868), Joe M. O’Sullivan (275899), David G. Hirst (282406), Huw D. Thomas (114714), Nicola J. Curtin (351064), Kim E. Cherry (692862), Patrick Keane (692866), Chris Shaw (285026), Kaye J. Williams (692869), Muhammad Babur (692864), Brian A. Telfer (692865), Thiagarajan Nambirajan (692867)   +16 more
core   +1 more source

Efficacy and safety of PARP inhibitor maintenance therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials

Frontiers in Pharmacology
BackgroundThe landscape of poly (ADP-ribose) polymerase (PARP) inhibitor treatment for ovarian cancer (OC) is continually evolving. This research aimed to evaluate the efficacy and safety of PARP inhibitors compared to placebo as a maintenance therapy ...
Guojuan Sun, Yi Liu
doaj   +1 more source

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)

BMC Cancer, 2021
Background ATLAS evaluated the efficacy and safety of the PARP inhibitor rucaparib in patients with previously treated locally advanced/unresectable or metastatic urothelial carcinoma (UC).
P. Grivas, Y. Loriot, R. Morales-Barrera, M. Y. Teo, Y. Zakharia, S. Feyerabend, N. J. Vogelzang, E. Grande, N. Adra, A. Alva, A. Necchi, A. Rodriguez-Vida, S. Gupta, D. H. Josephs, S. Srinivas, K. Wride, D. Thomas, A. Simmons, A. Loehr, R. L. Dusek, D. Nepert, S. Chowdhury   +21 more
doaj   +1 more source